Seattle Genetics announces first patient dosed in phase 2 trial of tisotumab vedotin
Seattle Genetics announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard treatment. June 13, 2018